Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SA article from yesterday:
http://seekingalpha.com/article/3727166-novartis-comes-under-fire-consider-newer-startup-imprimis-instead
The Express Scripts news is really interesting. Back in July 2014 Express Scripts dramatically scaled back coverage of compounded medications.
http://t.union-bulletin.com/news/2014/jul/11/express-scripts-cuts-payments-customized-drugs/?
Interesting that Express Scripts have noticed the value to the patient with this story. Hopefully, with a successful rollout of the daraprim alternative, they may realize there is a niche market and potential profitability in the compounding pharmacy industry as a disruptive technology for an exisitng problem with healthcare costs. With a market cap of 58.7 billion, they're not a bad friend to have.
Up big pm
Express Scripts Champions $1 per Pill Access to an Alternative for Daraprim
Source: PR Newswire (US)
ST. LOUIS, Dec. 1, 2015 /PRNewswire/ -- Express Scripts (NASDAQ: ESRX) today announced it will partner with Imprimis Pharmaceuticals (NASDAQ: IMMY) to drive access to a low-cost alternative to Daraprim (pyrimethamine), a drug for the treatment of toxoplasmosis that has been recently priced out of reach for people with HIV, pregnant women and others with weakened immune systems.
Imprimis is offering a compounded oral formulation of pyrimethamine and leucovorin (a form of folic acid) for $1 per capsule for people whose pharmacy benefit is managed by Express Scripts. While the 62-year-old Daraprim was priced $13.50 per pill earlier this year, its owner, Turing Pharmaceuticals, made the decision in September to increase the price to $750 per pill.
The companies expect that prescriptions for the pyrimethamine and leucovorin from Imprimis will be processed starting as early as this week for Express Scripts patients who need the treatment.
"Leveraging our expertise to improve access and affordability to an important medication is the right thing to do for HIV patients and others who could benefit from a combination of pyrimethamine and leucovorin," said Dr. Steve Miller, Senior Vice President and Chief Medical Officer of Express Scripts. "We believe we now have an extremely cost-effective way to provide access to a Daraprim alternative. We will share our solution with other payers to make sure all appropriate patients around the country have access to the treatment they need at the lowest possible price."
Working with leading organizations like Infectious Disease Society of America (IDSA) and the HIV Medicine Association (HIVMA), Express Scripts will help educate physicians on the value of prescribing this viable, far less expensive alternative to Daraprim.
Physicians will be able to send a patient-specific prescription for the combination formulation of pyrimethamine and leucovorin to Imprimis, which is now a part of the Express Scripts pharmacy network. Imprimis will compound the two drugs together into an alternative for patients.
"Our goal is always to put medicine within reach by making it more affordable and accessible," said Dr. Miller. "By partnering with like-minded partners at Imprimis, the IDSA and HIVMA who are passionate about patient care and access, we believe we can make great progress in delivering better health outcomes to people who suffer from toxoplasmosis."
"We are pleased to partner with Express Scripts to take positive action to counterbalance companies like Turing and others in order to address the growing drug pricing crisis in America," stated Mark L. Baum, CEO of Imprimis Pharmaceuticals. "Like Imprimis, Express Scripts believes in putting patients first and that the excessive drug price increases we have seen over the past few years, particularly for life saving medicines such as Daraprim, deserve our attention. In order to address these market needs, Imprimis formed the Imprimis Cares initiative to offer novel, high quality low cost alternative compounded formulations to help this at-risk patient population. We look forward to the expansion of the Imprimis Cares program and continuing our partnership with Express Scripts to identify and provide additional market based solutions to expensive single source, off patent drugs."
6.66 maybe
IMMy
Pricing come out?
People want in. I bet we gap up Monday.
That day it hit a low of 5. Smart move. I didn't have any powder available. Even teetered on selling into the panic. Emotions and trading vinegar and water. I thought it was going to hang around 5s 6s for a few weeks and I had some time to buy more in that range. Oops.
Trade at 8.00 ah
Imagine if 5-10M volume comes in here
http://elite.finviz.com/quote.ashx?t=IMMY
The dd is good on this one and ss and story is going to resurface in media again and again as long as they continue down this path
NVISION Eye Centers Sign National Account Agreement for Imprimis Pharmaceuticals' Ophthalmic Compounded Formulations
http://finance.yahoo.com/news/nvision-eye-centers-sign-national-133000257.html
Imprimis' Fight Against Martin Shkreli Is Part Of A Larger Battle
http://www.forbes.com/sites/davidkroll/2015/10/23/imiprimis-ceo-on-compounding-a-low-cost-alternative-to-turings-daraprim-for-toxoplasmosis/?utm_campaign=forbeshealth&utm_source=TWITTER&utm_medium=social&utm_channel=Business&linkId=18211025
KBIO
Seriously. This new Turing pharm news is definitely helping.
Thought it was only a matter of time before 7s. These low floats move on a sneeze. Nice recovery.
I'll add through January. 503b in Feb.
I'm buying more shares tomorrow!
Great piece about the trending compounding pharma industry:
Why "Price Gouging" May Come to an End
http://www.pharmalive.com/why-price-gougin-may-come-to-an-end/
Happy holiday, Westo!
That's a company I want to invest in. :)
Cheers ronk
Thought the same. Imagine a company like IMMY attempting to grow business with a patient-first mentality and an ethical brand. So old fashioned it just might work.
Of course he breaks his promise for a price cut. Surprise!
http://www.huffingtonpost.com/entry/turing-price-daraprim_565633c6e4b079b2818a31bc
This is a recent corporate presentation with a lot of good information page 30 gives the share structure with total stated as:
Total diluted outstanding 11,216,164
http://filecache.drivetheweb.com/ir1_imprimis/181/download/IMMY-Investor-Presentation-OCTOBER-27-10-2015.pdf
Do you happen to know an accurate authorized share account?
Absolutely. Been reading up a lot on this as I came across it while doing more reading on KB10. Immy Nice to see they are going to accommodate patients after the most hated CEO in America jacked up the price of his pill to $750. Just waiting on that 503B
I just realized it was a press release when I checked my brokerage account. But thank you for your direction.
It's under the news tab .
Nice find! Thank you!
Good news received today:
NVISION Eye Centers Sign National Account Agreement for Imprimis Pharmaceuticals' Ophthalmic Compounded Formulations
One of the largest LASIK and cataract surgery providers in the U.S. adopts Dropless Therapy™ injectables and LessDrops™ topical drops at its 24 U.S. centers in the Western United States
NVISION Eye Center patients may be able to reduce or eliminate the number of eye drops needed following cataract surgery, LASIK, and other ocular procedures.
Supply back up!
Of course. Econ 101!
Demand became higher than supply
Great read and analysis Ronk. Always a pleasure. No question there a computers at work trading and like that $700 sell order. I'll set mine to lock out the shorts.
I'm sticking around. Big things happening with the 503b facilities.
Correction: 503B should be completed by February. I said "a month or so". My mistake. Sorry.
Hard to say, Westo.
Did you happen to catch the KaloBios story and the etrader that got burned over $100,000 in minutes because he left his short position open and they shot up 800% aftermarket?
A lot of wall street news outlets have picked up the story and are wagging their fingers at inexperienced traders that don't realize a short play has limitless losses. Could be a lot of short positions closing or could be manipulation. Could be insiders buying but I doubt that. Not when we're a month or so away from the 503B.
I really believe this is just going to be really volatile for a while. Happy to see it recover but overall, feeling unemotional because I'm long. I don't have a stop on this because big money can see stops and use it to their advantage and I have a sell order for a price of over $700 pps so my shares can't be borrowed and leant to short sellers.
If you're not familiar, research algorithm trading and spoofing. I've posted on another board about it. It dawned on me that the market may be highly manipulated based on one key figure:
"According to the NYSE Factbook, the average holding period for stocks in 1960 was 100 months (8 years). By 1970 it had dropped to 63 months (5 years). By 1980 it had dropped to 33 months, by 1990 to 26 months, by 2000 to just 14 months, and in 2010 just six months."
According to updated information, some estimates say the average time to hold currently is 11 - 24 seconds. Hard not to believe there are computers involved. And like I said earlier, the only way to beat high frequency trading is low frequency trading. GL! Nice to see you're still hanging in there.
Yup! Biotech's a gamble if someone is swing trading, for sure. Expect volatility. But while there are huge 20-30% swings on these, they pop all the time. Consider that etrader that left a short position on KB10 open after hours and lost his shirt. Opens a gofundme page to bail him out.
The only way to beat high frequency trading is low frequency trading.
My plan exactly. They're growing the right way and still improving their outlook rapidly. Once the first 503B in Texas is finished in February and the 2nd 503B is completed in the 2nd quarter, I think the numbers will really pop and the balance sheet is going to even out and real value will be realized.
Water is gonna be choppy. It's volatile. Dollar cost average is the way to play long with unpredictable volatility. GL!
I went ahead and bought on the dip. It brought my cost average down nicely. I'm looking forward to the Q4 reports, as I know they got a lot of new business after the Daraprim incident. That plus their plans for the future means I'm long on this company. :)
The Q actually beat analysts projections. Then there was a small hit piece that came out today by Louis Navellier.
Waiting for some of my other plays to take off and will buy more.
This will be volatile until the P/E ratio is positive.
This historically has tested 5 before. I thought it might do the same until the 503B facilities are operational.
Pretty scabby looking after all the promo
Followers
|
59
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3167
|
Created
|
07/01/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |